Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 9.02 USD -5.55% Market Closed
Market Cap: 1B USD

Wall Street
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 22.12 USD with a low forecast of 4.04 USD and a high forecast of 111.3 USD.

Lowest
Price Target
4.04 USD
55% Downside
Average
Price Target
22.12 USD
145% Upside
Highest
Price Target
111.3 USD
1 134% Upside
Intellia Therapeutics Inc Competitors:
Price Targets
LENZ
Graphite Bio Inc
196% Upside
145020
Hugel Inc
72% Upside
NVAX
Novavax Inc
97% Upside
TVTX
Travere Therapeutics Inc
22% Upside
ARWR
Arrowhead Pharmaceuticals Inc
15% Downside
ACAD
ACADIA Pharmaceuticals Inc
10% Upside
ZEAL
Zealand Pharma A/S
55% Upside
GNS
Genus PLC
18% Upside

Revenue
Forecast

Revenue Estimate
Intellia Therapeutics Inc

For the last 9 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 29%. The projected CAGR for the next 4 years is 85%.

29%
Past Growth
85%
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NTLA's stock price target?
Price Target
22.12 USD

According to Wall Street analysts, the average 1-year price target for NTLA is 22.12 USD with a low forecast of 4.04 USD and a high forecast of 111.3 USD.

What is Intellia Therapeutics Inc's Revenue forecast?
Projected CAGR
85%

For the last 9 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 29%. The projected CAGR for the next 4 years is 85%.

Back to Top